Silo Pharma Inc. a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has entered into a Joint Venture with Zylo Therapeutics.   This Joint Venture will utilize Zylo’s innovative sustained release topical delivery system that was originally developed at Albert Einstein College of Medicine using Silo Pharma’s expertise in the use of psychedelics. The joint venture will initially explore the clinical development of ketamine using ZTI’s Z-pod techno...